A5000741843- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- Advanced Radiotherapy Techniques
- Cytokine Signaling Pathways and Interactions
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- MRI in cancer diagnosis
- Urological Disorders and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Urinary Tract Infections Management
- Urinary Bladder and Prostate Research
- Radiomics and Machine Learning in Medical Imaging
- Global Cancer Incidence and Screening
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Statistical Methods in Clinical Trials
- Surgical Simulation and Training
- Economic and Financial Impacts of Cancer
- Molecular Biology Techniques and Applications
- BRCA gene mutations in cancer
Thomas Jefferson University
2016-2025
Sidney Kimmel Cancer Center
2016-2025
Einstein Medical Center Philadelphia
2023-2025
Einstein Healthcare Network
2023-2024
Penn State Milton S. Hershey Medical Center
2020-2024
Philadelphia University
2011-2020
Thomas Jefferson University Hospital
2009-2020
Nashville Oncology Associates
2020
Augusta University
2020
Temple University Hospital
2020
Purpose Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC); however, it infrequently adopted in practice because concerns regarding toxicity and delay to cystectomy. We hypothesized that three cycles neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, cisplatin (AMVAC) would be safe, shorten the time surgery, yield similar pathologic complete response (pT0) rates compared with historical controls. Patients Methods cT2-T4a N0-N1...
Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary assessment. Critical needs include optimized multigene strategies that incorporate evolving genetic data, consistency in GT indications alternate evaluation models address the rising demand for services. A multidisciplinary consensus conference included experts, stakeholders, national organization leaders was convened response to current practice challenges develop implementation...
The optimal timing of postoperative radiotherapy (RT) after radical prostatectomy (RP) is unclear. We hypothesized that a genomic classifier (GC) would provide prognostic and predictive insight into the development clinical metastases in men receiving post-RP RT inform decision making.
Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework groups. We aimed develop novel clinical-genomic grouping system can readily be incorporated guidelines cancer. Materials and Methods Two multicenter cohorts (n = 991) were used training validation groups, two additional 5,937) reclassification analyses. Competing risks analysis...
BackgroundPatients with Bacillus Calmette–Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell–activating interleukin-15 (IL-15) superagonist Nogapendekin alfa inbakicept (NAI), also known as N-803, may act synergistically BCG to elicit durable complete responses (CRs) in this patient population.MethodsIn open-label, multicenter study, patients BCG-unresponsive carcinoma situ (CIS) or without Ta/T1 papillary disease were treated...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Nov 2003Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain Specific Membrane Antigen NEIL H. BANDER, EDOUARD J. TRABULSI, LALE KOSTAKOGLU, DANIEL YAO, SHANKAR VALLABHAJOSULA, PETER SMITH-JONES, MAUREEN A. JOYCE, MATTHEW MILOWSKY, DAVID M. NANUS, and STANLEY GOLDSMITH BANDERNEIL BANDER , TRABULSIEDOUARD TRABULSI KOSTAKOGLULALE KOSTAKOGLU YAODANIEL YAO VALLABHAJOSULASHANKAR...
The detection of prostate cancer relies primarily on abnormal digital rectal examination or increased serum specific antigen concentration. However, low positive predictive values result in many men with and/or suspicious having a negative biopsy. We investigated the value PCA3 (prostate gene 3) urine test predicting likelihood diagnosis before biopsy.We performed prospective, community based clinical trial to evaluate score any This was conducted at 50 urology practices United States....
PurposeTo test the hypothesis that a genomic classifier (GC) would predict biochemical failure (BF) and distant metastasis (DM) in men receiving radiation therapy (RT) after radical prostatectomy (RP).Methods MaterialsAmong patients who underwent post-RP RT, 139 were identified for pT3 or positive margin, did not receive neoadjuvant hormones had paraffin-embedded specimens. Ribonucleic acid was extracted from highest Gleason grade focus applied to high-density-oligonucleotide microarray....
The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis is a critical modulator of cell cycle entry and aberrant in many human cancers. New nodes therapeutic intervention are needed that can delay or combat the onset malignancies. antitumor properties mechanistic functions PD-0332991 (PD; potent selective CDK4/6 inhibitor) were investigated using prostate cancer (PCa) models primary tumors. PD significantly impaired capacity PCa cells to proliferate by promoting robust G1-arrest....
Data supporting neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated pathological complete responses after carcinoma.Patients with in whom nephroureterectomy was planned were assigned to 4 cycles accelerated methotrexate, vinblastine, doxorubicin and cisplatin those baseline creatinine clearance greater than 50 ml per minute or gemcitabine carboplatin 30 less. The study primary end point a...
No AccessJournal of UrologyAdult Urology1 May 2018Efficacy and Safety Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance Bladder Cancer: A Phase III, Comparative, Multicenter Studyis corrected byERRATUM Siamak Daneshmand, Sanjay Patel, Yair Lotan, Kamal Pohar, Edouard Trabulsi, Michael Woods, Tracy Downs, William Huang, Jeffrey Jones, O’Donnell, Trinity Bivalacqua, Joel DeCastro, Gary Steinberg, Ashish Kamat, Matthew Resnick, Badrinath Konety, Mark Schoenberg, J....
Abstract Purpose: To improve the outcomes of patients with castration-resistant prostate cancer (CRPC), there is an urgent need for more effective therapies and approaches that individualize specific treatments CRPC. These studies compared novel taxane cabazitaxel previous generation docetaxel, aimed to determine which tumors are most likely respond. Experimental design: Cabazitaxel docetaxel were via in vitro modeling molecular mechanism, biochemical cell biologic impact, proliferation, was...
To report on the 15-year prostate cancer experience of our multidisciplinary genitourinary clinic established in 1996 at National Cancer Institute (NCI) -designated Jefferson Kimmel Center. Patients with cancers were evaluated weekly by multiple specialists a single site, and we focus 83% patients cancer. knowledge, is longest continuously operating center its kind an NCI Center United States.Data from Jefferson's Oncology Data Services compared to SEER outcomes. treatment changes localized...
Despite salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) after radical prostatectomy (RP), some patients still progress to metastases. Identifying these men would allow them undergo systemic including testing novel therapies reduce metastases risk. To test whether the genomic classifier (GC) predicts development of metastatic disease. Retrospective multi-center and multi-ethnic cohort study from two academic centers one Veterans Affairs Medical Center in United States...